evidence of receiving any CDT For patients with metastatic disease, we described the therapy they received (see Table 1 for therapies). Table 1. Therapy Characteristics for Patients With BC by Stage at Diagnosis Assessing Loss to Follow
Search Results
Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt
Lindsay M. Sabik, Kirsten Y. Eom, Zhaojun Sun, Jessica S. Merlin, Hailey W. Bulls, Patience Moyo, Jennifer A. Pruskowski, G.J. van Londen, Margaret Rosenzweig, and Yael Schenker
cancer diagnosis using chi-square tests. We then estimated multivariable logistic regression models to assess the association of patient characteristics, previous opioid receipt, treatment category, and year of diagnosis with receipt of an opioid
Marieke Pape, Steven C. Kuijper, Pauline A.J. Vissers, Laurens V. Beerepoot, Geert-Jan Creemers, Hanneke W.M. van Laarhoven, and Rob H.A. Verhoeven
resection (resection of primary tumor ± perioperative treatment), chemoradiotherapy, systemic therapy, or BSC. Statistical Analysis Characteristics were noted with frequencies and percentages or mean and standard deviation. OS was assessed from the
Emily C. Harrold, Ahmad F. Idris, Niamh M. Keegan, Lynda Corrigan, Min Yuen Teo, Martin O’Donnell, Sean Tee Lim, Eimear Duff, Dearbhaile M. O’Donnell, M. John Kennedy, Sue Sukor, Cliona Grant, David G. Gallagher, Sonya Collier, Tara Kingston, Ann Marie O’Dwyer, and Sinead Cuffe
independent predictors of insomnia syndrome. Results Demographic and Clinical Characteristics Of the 337 patients invited to participate, 87% consented to study inclusion (n=294); 12 declined without explanation, 15 were too unwell to participate, 8 declined
Kazzem Gheybi, Jue Jiang, Shingai B.A. Mutambirwa, Pamela X.Y. Soh, Zsofia Kote-Jarai, Weerachai Jaratlerdsiri, Rosalind A. Eeles, M.S. Riana Bornman, and Vanessa M. Hayes
Research Ethics Committee in Sydney, Australia (#SVH15/227). Table 1. Patient Characteristics Through genome-wide interrogation of 7,472,833 biallelic single-nucleotide variants (SNVs), all patients were classified genetically as being of African
into clinical care paths. Further, cancer treatment is becoming increasingly personalized to the patient and tumor characteristics, thus increasing the complexity of decision-making. Methods: We developed a method to model guideline recommendations
Kah Poh Loh, Maya Abdallah, Meng-Shiou Shieh, Mihaela S. Stefan, Penelope S. Pekow, Peter K. Lindenauer, Supriya G. Mohile, Dilip Babu, and Tara Lagu
are reliably coded. Patient and Clinical Characteristics We collected demographics including age, sex, race, insurance provider, comorbidities (modified combined comorbidity score derived from the Elixhauser and Charlson comorbidity index
Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani
mortality data with results from published literature and the SEER database. Flatiron’s mortality data are estimated to have a sensitivity of 85% to 90%, specificity of 97% to 98%, and accuracy of 95% to 97%. 15 Baseline Characteristics Demographic and
Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton
2014. In addition to the traditional demographic and tumor characteristics collected by SEER, the SEER POC study collected additional variables in a sample of patients from various SEER registries. For stage IV colon cancer, these variables included the
Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff
regions. Currently, SEER covers approximately 28% of the US population. 7 Information for each patient in SEER is primarily obtained from hospital records and includes tumor characteristics, treatment, and select demographic characteristics. Given that
